蜜桃传媒

• share
• favorite_border

鈥� Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors 鈥� One patient experienced a complete response, and one patient had a partial response 鈥� This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less 鈥� AIC100 is a CAR T cell therapy that targets the ICAM-1 protein on tumor cells

• share
• favorite_border

鈥� Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer

• share
• favorite_border

鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

• share
• favorite_border

路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

• share
• favorite_border

鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer.

• share
• favorite_border

Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at the American Association for Cancer Research (AACR) Annual Meeting 2025.

• share
• favorite_border

John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology at The University of Texas MD Anderson Cancer Center, has been elected to the 2025 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of decades of combined laboratory and computational work pioneering multi-omic molecular profiling, including the introduction of new laboratory techniques, clustered heat maps, and early innovations in artificial intelligence for cancer drug discovery.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services and MD Anderson鈥檚 unparalleled patient experience closer to those living in Southwest Houston and the surrounding areas.

• share
• favorite_border

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph.D., from The University of Texas MD鈥疉nderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS).

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced that Jeffrey E. Lee, M.D., an internationally regarded leader in the field of oncology, has been appointed chief medical executive (CME) effective April 1.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced a $9 million gift from the F. W. Bert and Mae Dean Wheeler Foundation to establish the F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published today in Nature Cancer, the new approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Texas Children鈥檚 Hospital have announced a transformational collaboration dedicated solely to pediatric cancer care. The collaboration has a single mission: to end childhood cancer.